4-Benzyl-1H-imidazoles with oxazoline termini as histamine H3 receptor agonists

Journal of Medicinal Chemistry

Volumn 51, Issue 10, 2008, Pages 2944-2953

  Wijtmans, Maikel ^a   Celanire, Sylvain ^b   Snip, Erwin ^a   Gillard, Michel R ^b   Gelens, Edith ^a   Collart, Philippe P ^b   Venhuis, Bastiaan J ^a   Christophe, Bernard ^b   Hulscher, Saskia ^a   Van Der Goot, Henk ^a   Lebon, Florence ^b   Timmerman, Henk ^a   Bakker, Remko A ^a   Lallemand, Bénédicte I L F ^b   Leurs, Rob ^a   Talaga, Patrice E ^b   De Esch, Iwan J P ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b UCB   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYNE DERIVATIVE; HISTAMINE H3 RECEPTOR AGONIST; IMIDAZOLE DERIVATIVE; OXAZOLINE DERIVATIVE;

AGONIST; ARTICLE; BINDING AFFINITY; CHEMICAL ANALYSIS; HIGH THROUGHPUT SCREENING; LIPOPHILICITY; MEDICAL RESEARCH;

ANIMALS; CHO CELLS; COMBINATORIAL CHEMISTRY TECHNIQUES; CRICETINAE; CRICETULUS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; GUINEA PIGS; HISTAMINE AGONISTS; HUMANS; IMIDAZOLES; INTESTINES; MODELS, MOLECULAR; MUSCLE CONTRACTION; MUSCLE, SMOOTH; OXAZOLES; PROTEIN BINDING; RADIOLIGAND ASSAY; RECEPTORS, HISTAMINE H3; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 43949083386     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm7014149     Document Type: Article

References (63)

1. Hough, L. B. Genomics meets histamine receptors: new subtypes, new receptors. Mol. Pharmacol. 2001, 59, 415-419.
2. Oda, T.; Morikawa, N.; Saito, Y.; Masuho, Y.; Matsumoto, S. Molecular cloning and characterization of a novel type of histamine receptor preferentially expressed in leukocytes. J. Biol. Chem. 2000, 275, 36781-36786.
3. 4 receptor in autoimmune disease. Expert Opin. Invest. Drugs. 2006, 15, 1443-1452.
4. Lim, H. D.; Smits, R. A.; Leurs, R.; de Esch, I. J. P. The emerging role of the histamine H-4 receptor in anti-inflammatory therapy. Curr. Top. Med. Chem. 2006, 6, 1365-1373.
5. 3) of histamine receptor. Nature 1983, 302, 832-837.
6. 3 heteroreceptors. In The Histamine H3 Receptor: A Target for New Drugs; Leurs, R., Timmerman, H., Eds.; Elsevier. Amsterdam, 1998; pp 13-16.
7. 3-receptors. Neuroscience 1985, 15, 553-562.
8. 3 receptor. Mol. Pharmacol. 1999, 55, 1101-1107.
9. 3 receptor drugs. Nat. Rev. Drug Discovery 2005, 4, 107-120.
10. 3 receptor antagonists reach out for the clinic. Drug Discovery Today 2005, 10, 1613-1627.
11. 3 receptors regulates histamine neurons in brain. Nature 2000, 408, 860-864.
12. Wieland, K.; Bongers, G.; Yamamoto, Y.; Hashimoto, T.; Yamatodani, A.; Menge, W. M. B. P.; Timmerman, H.; Lovenberg, T. W.; Leurs, R. Constitutive activity of histamine H-3 receptors stably expressed in SK-N-MC cells: Display of agonism and inverse agonism by H-3 antagonists. J. Pharmacol. Exp. Ther. 2001, 299, 908-914.
13. 3 receptor antagonists: preclinical promise for treating obesity and cognitive disorders. Mol. Interv. 2006, 6, 77-78.
14. 3 receptor antagonists: from target identification to drug leads. Biochem. Pharmacol. 2007, 73, 1084-1096.
15. 3 receptor ligands break ground in a remarkable plethora of therapeutic areas. Expert Opin. Invest. Drugs 2007, 16, 1-19.
16. 3 receptor. Prog. Med. Chem. 2006, 44, 181-206.
17. 3 receptor agonist prodrug. J. Pharmacol. Exp. Ther. 1997, 281, 1085-1094.
18. 3 receptor agonist, inhibits central neurogenic vascular inflammation and produces sedation in the guinea pig. J. Pharmacol. Exp. Ther. 1998, 287, 43-50.
19. Shih, N. Y.; Aslanian, R.; Lupo, A. T.; Orlando, S.; Piwinski, J. J.; Green, M. J.; Ganguly, A. K.; West, R.; Tozzi, S.; Kreutner, W.; Hey, J. A. Trans-4-methyl-3-imidazoyl pyrrolidine as a potent, highly selective histamine H-3 receptor agonist in vivo. Bioorg. Med. Chem. Lett. 1998, 8, 243-248.
20. de Esch, I. J. P.; Belzar, K. J. Histamine H-3 receptor agonists. Mini-Rev. Med. Chem. 2004, 4, 955-963.
21. Millán-Guerrero, R. O.; Isais-Millán, R.; Benjamín, T.-H.; Tene, C. E. N-α-Methylhistamine safety and efficacy in migraine prophylaxis: phase III study. Can. J. Neurol. Sci. 2006, 33, 195-199.
22. 3 receptor agonist for the treatment of obesity and diabetes mellitus. Proc. Natl. Acad. Sci. U.S.A. 2006, 103, 13866-13871.
23. 3 histamine receptor agonist inhibits biliary growth of BDL rats by downregulation of the cAMP-dependent PKA/ERK1/2/ELK-1 pathway. Lab. Invest. 2007, 87, 473-487.
24. Teuscher, C.; Subramanian, M.; Noubade, R.; Gao, J. F.; Offner, H.; Zachary, J. F.; Blankenhorn, E. P. Central histamine H-3 receptor signaling negatively regulates susceptibility to autoimmune inflammatory disease of the CNS. Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 10146-10151.
25. 3 receptor agonist. J. Med. Chem. 2005, 48, 2100-2107.
26. Kitbunnadaj, R.; Zuiderveld, O. P.; Christophe, B.; Hulscher, S.; Menge, W. M. P. B.; Gelens, E.; Snip, E.; Bakker, R. A.; Celanire, S.; Gillard, M.; Talaga, P.; Timmerman, H.; Leurs, R. Identification of 4-(1H-imidazol- 4(5)-ylmethyl)pyridine (immethridine) as a novel, potent, and highly selective histamine H-3 receptor agonist. J. Med. Chem. 2004, 47, 2414-2417.
27. Kitbunnadaj, R.; Hoffmann, M.; Fratantoni, S. A.; Bongers, G.; Bakker, R. A.; Wieland, K.; el Jilali, A.; de Esch, I. J. P.; Menge, W. M. P. B.; Timmerman, H.; Leurs, R. New high affinity H-3 receptor agonists without a basic side chain. Bioorg. Med. Chem. 2005, 13, 6309-6323.
28. de Esch, I. J. P.; Timmerman, H.; Menge, W. M. P. B.; Nederkoorn, P. H. J. A qualitative model for the histamine H-3 receptor explaining agonistic and antagonistic activity simultaneously. Arch. Pharm. 2000, 333, 254-260.
29. Yao, B. B.; Hutchins, C. W.; Carr, T. L.; Cassar, S.; Masters, J. N.; Bennani, Y. L.; Esbenshade, T. A.; Hancock, A. A. Molecular modeling and pharmacological analysis of species-related histamine H-3 receptor heterogeneity. Neuropharmacology 2003, 44, 773-786.
30. 3 receptor. J. Pharmacol. Exp. Ther. 2002, 301, 451-458.
31. Sasse, A.; Stark, H.; Ligneau, X.; Elz, S.; Reidemeister, S.; Ganellin, C. R.; Schwartz, J. C.; Schunack, W. (Partial) agonist/antagonist properties of novel diarylalkyl carbamates on histamine H-3 receptors. Bioorg. Med. Chem. 2000, 8, 1139-1149.
32. Pelloux-Leon, N.; Fkyerat, A.; Piripitsi, A.; Tertiuk, W.; Schunack, W.; Stark, H.; Garbarg, M.; Ligneau, X.; Arrang, J. M.; Schwartz, J. C.; Ganellin, C. R. Meta-substituted aryl(thio)ethers as potent partial agonists (or antagonists) for the histamine H-3 receptor lacking a nitrogen atom in the side chain. J. Med. Chem. 2004, 47, 3264-3274.
33. Wulff, B. S.; Hastrup, S.; Rimvall, K. Characteristics of recombinantly expressed rat and human histamine H-3 receptors. Eur. J. Pharmacol. 2002, 453, 33-41.
34. 3 receptors in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 11086-11091.
35. Turner, R. M.; Lindell, S. D.; Ley, S. V. A facile route to imidazol-4-yl anions and their reaction with carbonyl compounds. J. Org. Chem. 1991, 56, 5739-5740.
36. Vollinga, R. C.; Menge, W. M. P. B.; Leurs, R.; Timmerman, H. Homologs of histamine as histamine H-3 receptor antagonists: a new potent and selective H-3 antagonist, 4(5)-(5-aminopentyl)-1H-imidazole. J. Med. Chem. 1995, 38, 266-271.
37. Lutzen, A.; Hapke, M. Synthesis of 5-substituted 2,2′-bipyridines from substituted 2-chloropyridines by a modified Negishi cross-coupling reaction. Eur. J. Org. Chem. 2002, 2292-2297.
38. Allen, A. D.; Chiang, Y.; Kresge, A. J.; Tidwell, T. T. Substituent effects on the acid hydration of acetylenes. J. Org. Chem. 1982, 47, 775-779.
39. Phillips, A. J.; Uto, Y.; Wipf, P.; Reno, M. J.; Williams, D. R. Synthesis of functionalized oxazolines and oxazoles with DAST and Deoxo-Fluor. Org. Lett. 2000, 2, 1165-1168.
40. 3 receptor antagonist based on the 4-benzyl-(1H-imidazol-4-yl) template. Bioorg. Med. Chem. Lett. 2002, 12, 937-941.
41. 3-receptor antagonist N-(3,5-dichlorophenyl)- N′-[[4-(1H-imidazol-4-ylmethyl)phenyl]-methyl]-urea (SCH79687). J. Pharmacol. Exp. Ther. 2003, 305, 1037-1044.
42. Tedford, C. E.; Phillips, J. G.; Gregory, R.; Panlowski, G. P.; Fadnis, L.; Khan, M. A.; Ali, S. M.; Handley, M. K.; Yates, S. L. Development of trans-2-[1H-imidazol-4-yl] cyclopropane derivatives as new high-affinity histamine H-3 receptor ligands. J. Pharmacol. Exp. Ther. 1999, 289, 1160-1168.
43. Ali, S. M.; Tedford, C. E.; Gregory, R.; Handley, M. K.; Yates, S. L.; Hirth, W. W.; Phillips, J. G. Design, synthesis, and structure-activity relationships of acetylene-based histamine H-3 receptor antagonists. J. Med. Chem. 1999, 42, 903-909.
44. de Esch, I. J. P.; Mills, J. E. J.; Perkins, T. D. J.; Romeo, G.; Hoffmann, M.; Wieland, K.; Leurs, R.; Menge, W. M. P. B.; Nederkoorn, P. H. J.; Dean, P. M.; Timmerman, H. Development of a pharmacophore model for histamine H-3 receptor antagonists, using the newly developed molecular modeling program SLATE. J. Med. Chem. 2001, 44, 1666-1674.
45. Ambache, N.; Killick, S. W.; Zar, M. A. Antagonism by burimamide of inhibitions Induced by histamine in plexus-containing longitudinal muscle preparations from guinea pig ileum. Br. J. Pharmacol. 1973, 48, P362-P363.
46. Daniel, E. E.; Kwan, C. Y.; Janssen, L. Pharmacological techniques for the in vitro study of intestinal smooth muscles. J. Pharmacol. Toxicol. 2001, 45, 141-158.
47. Trzeciakowski, J. P. Inhibition of guinea pig ileum contractions mediated by a class of histamine-receptor resembling the H-3 subtype. J. Pharmacol. Exp. Ther. 1987, 243, 874-880.
48. Hew, R. W. S.; Hodgkinson, C. R.; Hill, S. J. Characterization of histamine H-3 receptors in guinea pig ileum with H-3 selective ligands. Br. J. Pharmacol. 1990, 101, 621-624.
49. Taylor, S. J.; Kilpatrick, G. J. Characterization of histamine-H-3 receptors controlling nonadrenergic noncholinergic contractions of the guinea pig isolated ileum. Br. J. Pharmacol. 1992, 105, 667-674.
50. Menkveld, G. J.; Timmerman, H. Inhibition of electrically evoked contractions of guinea pig ileum preparations mediated by the histamine H3-receptor. Eur. J. Pharmacol. 1990, 186, 343-347.
51. app) and intrinsic activity (alpha) from functional bioassays. Br. J. Pharmacol. 2007, 151, 128-143.
52. Tedford, C. E.; Hoffmann, M.; Seyedi, N.; Maruyama, R.; Levi, R.; Yates, S. L.; Ali, S. M.; Phillips, J. G. High antagonist potency of GT-2227 and GT-2331, new histamine H-3 receptor antagonists, in two functional models. Eur. J. Pharmacol. 1998, 351, 307-311.
53. Lorenzi, S.; Mor, M.; Bordi, F.; Rivara, S.; Rivara, M.; Morini, G.; Bertoni, S.; Ballabeni, V.; Barocelli, E.; Plazzi, P. V. Validation of a histamine H-3 receptor model through structure-activity relationships for classical H-3 antagonists. Bioorg. Med. Chem. 2005, 13, 5647-5657.
54. 3-receptor: a molecular modeling study of a G-protein coupled receptor, Ph.D. Thesis, Heinrich-Heine-Universität, Dusseldorf, Germany, 2005.
55. Clitherow, J. W.; Beswick, P.; Irving, W. J.; Scopes, D. I. C.; Barnes, J. C.; Clapham, J.; Brown, J. D.; Evans, D. J.; Hayes, A. G. Novel 1,2,4-oxadiazoles as potent and selective histamine H-3 receptor antagonists. Bioorg. Med. Chem. Lett. 1996, 6, 833-838.
56. Moureau, F.; Neuwels, M.; Dogimont, C.; Goldstein, S.; Massingham, R. Conformational analysis of pseudo-peptides: The case of FK888, a potent and selective substance P receptor antagonist. Lett. Pept. Sci. 1998, 5, 155-158.
57. Celanire, S.; Lebon, F.; Stark, H. Drug Discovery: From Hits to Clinical Candidates. In The Third Histamine Receptor: Selective Ligands as Potential Therapeutic Agents in CNS Disorders; Vohora, D. S. , Ed.; Taylor & Francis CRC Press Inc.: Boca Raton, FL, 2007; in press.
58. 4 receptor agonist. J. Pharmacol. Exp. Ther. 2005, 314, 1310-1321.
59. Gbahou, F.; Vincent, L.; Humbert-Claude, M.; Tardivel-Lacombe, J.; Chabret, C.; Arrang, J. M. Compared pharmacology of human histamine H-3 and H-4 receptors: structure-activity relationships of histamine derivatives. Br. J. Pharmacol. 2006, 147, 744-754.
60. 3 receptor antagonists with human adrenal cytochrome P450 enzymes. Pharmacology 2002, 66, 128-135.
61. 3 receptor antagonists based on the 4-[(1H-imidazol-4-yl)methyl]piperidine scaffold. Bioorg. Med. Chem. Lett. 2006, 16, 395-399.
62. Zhang, M.; Ballard, M. E.; Pan, L. P.; Roberts, S.; Faghih, R.; Cowart, M.; Esbenshade, T. A.; Fox, G. B.; Decker, M. W.; Hancock, A. A.; Rueter, L. E. Lack of cataleptogenic potentiation with non-imidazole H-3 receptor antagonists reveals potential drug-drug interactions between imidazole-based H-3 receptor antagonists and antipsychotic drugs. Brain Res. 2005, 1045, 142-149.
63. Celanire, S.; Talaga, P.; Leurs, R.; Denonne, F.; Timmerman, H.; Lebon, F. Compounds comprising an oxazoline or thiazoline moiety, processes for making them and their uses. World Patent WO2006103057. 2006.